BNP Paribas Financial Markets
PHAT icon

BNP Paribas Financial Markets’s Phathom Pharmaceuticals PHAT Stock Holding History

BNP Paribas Financial Markets’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$126K Buy
11,332
+1,542
+16% +$19.5K ﹤0.01% 4261
2025
Q4 		$162K Buy
9,790
+962
+11% +$13.7K ﹤0.01% 4154
2025
Q3 		$104K Buy
8,828
+3,756
+74% +$38.8K ﹤0.01% 4278
2025
Q2 		$48.6K Buy
5,072
+2,122
+72% +$11.7K ﹤0.01% 4265
2025
Q1 		$18.5K Sell
2,950
-36,582
-93% -$222K ﹤0.01% 4559
2024
Q4 		$321K Buy
+39,532
New +$490K ﹤0.01% 3585

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

BNP Paribas Financial Markets's PHAT Position: Q1 2026 in Review

BNP Paribas Financial Markets increased its Phathom Pharmaceuticals (PHAT) stake by 16% in Q1 2026, buying an estimated $19.5K and bringing the position to 11,332 shares worth $126K. The position accounts for ﹤0.01% of the portfolio, ranked #4261.

BNP Paribas Financial Markets first reported a position in PHAT in Q4 2024 and has held it in 6 quarters since. The position peaked at $321K in Q4 2024. 174 funds tracked by Wall St. Rank hold PHAT as of Q1 2026.

  • BNP Paribas Financial Markets held 11,332 shares of Phathom Pharmaceuticals worth $126K as of Q1 2026.
  • BNP Paribas Financial Markets bought 1,542 Phathom Pharmaceuticals shares in Q1 2026, an estimated $19.5K.
  • Phathom Pharmaceuticals made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q1 2026, its #4261 holding.
  • BNP Paribas Financial Markets first reported a position in Phathom Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
  • BNP Paribas Financial Markets's Phathom Pharmaceuticals position peaked at $321K in Q4 2024.
  • 174 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q1 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q1 2026, filed 12 May 2026.